Amphetamine
Amphetamine (e.g., Adderall) is a prescription stimulant for ADHD and narcolepsy; misuse strains the heart, can cause dependence and psychosis, and is dangerous combined with other drugs.
Overview
Amphetamine is a prescription stimulant, most familiar as the mixed amphetamine salts sold under the brand name Adderall, used to treat attention-deficit/hyperactivity disorder (ADHD), narcolepsy, and (in some formulations) binge-eating disorder. Taken as prescribed under medical supervision it can improve attention and reduce impulsivity and hyperactivity, but it is a controlled substance with a recognized potential for misuse, dependence, and addiction. Misuse — taking more than prescribed, using it without a prescription (for example to study or stay awake), or taking it by routes other than swallowing — raises the risks substantially. Regulators have strengthened warnings about the serious risks of prescription stimulants, including misuse, addiction, overdose, and death.
Source: NIDA; FDA; DEA
Chemistry & mechanism of action
Amphetamine increases the activity of the neurotransmitters dopamine and norepinephrine in the brain, boosting alertness, attention, and energy and, at higher doses, producing euphoria that can reinforce repeated use. The same stimulation activates the cardiovascular system, raising heart rate and blood pressure. In people with ADHD, carefully dosed stimulant medication can improve focus; at higher or misused doses the same mechanisms drive the drug's dangers — cardiovascular strain, agitation, and, with heavy use, disruption of normal dopamine signaling that can affect mood and behavior. With repeated misuse, tolerance and dependence can develop.
Source: NIDA; PubChem CID 3007
Effects
At therapeutic doses, amphetamine improves attention and wakefulness and can suppress appetite. Common effects, especially at higher or misused doses, include increased energy and alertness, euphoria, talkativeness, reduced appetite, insomnia, dry mouth, and a faster heartbeat. As the dose rises, effects can include anxiety, restlessness, irritability, raised blood pressure, and — at high doses or with heavy use — paranoia, hallucinations, and stimulant psychosis. Coming down can bring fatigue, low mood, and difficulty concentrating. Long-term misuse is associated with cardiovascular problems, weight loss, sleep disruption, and mental-health effects.
Source: NIDA; FDA
Risks & harms
The main acute danger is cardiovascular: amphetamine raises heart rate and blood pressure and can, particularly at high doses or in people with underlying heart conditions, contribute to dangerously high blood pressure, irregular heart rhythms, heart attack, stroke, seizures, or dangerously high body temperature. Unlike opioids, there is no reversal medication for a stimulant overdose — emergency care is the response, so chest pain, severe agitation, very high temperature, or seizures mean calling 911. Combining amphetamine with other stimulants (including cocaine or large amounts of caffeine) compounds cardiovascular strain, and combining it with opioids or other depressants is dangerous because the stimulant can mask sedation and lead to taking more of the depressant. Heavy or high-dose use can trigger stimulant psychosis. Misuse can lead to dependence, and any pill obtained outside a licensed pharmacy can be a counterfeit containing other substances, including fentanyl, so naloxone is worth having on hand. For poisoning guidance call Poison Control at 1-800-222-1222; for substance-use support the SAMHSA National Helpline is 1-800-662-4357.
Source: NIDA; FDA; SAMHSA
Legal status (US)
In the United States, amphetamine (including the mixed amphetamine salts in Adderall) is a Schedule II controlled substance under the Controlled Substances Act: accepted medical uses but a high potential for abuse and dependence, so it is tightly regulated, prescriptions cannot be refilled, and possessing or sharing it without a valid prescription is illegal. Internationally, amphetamine is controlled under the United Nations Convention on Psychotropic Substances (1971), with penalties varying by country. For country-by-country legal detail, see our legality pages.
Source: DEA; UN Convention on Psychotropic Substances (1971)
Drug laws and enforcement change and vary by country. This is not legal advice. Always confirm with the destination’s embassy or official drug authority before traveling, because penalties can be severe, including imprisonment.
Before you travel
Verify current rules with the destination country’s official drug authority and your own country’s embassy before traveling. Find the destination’s U.S. embassy & official country guidance →
Non-U.S. travelers: check your own government’s travel advisory and embassy.
If you’re detained or arrested abroad
Contact your own country’s embassy or consulate in the destination immediately, not the destination’s authorities. U.S. citizens: contact the nearest U.S. embassy/consulate and the U.S. State Department at +1-202-501-4444 (from abroad). If a U.S. citizen is arrested or detained abroad →
Images
Visual references coming soon.
If it’s too intense
If an experience becomes overwhelming, the goal is to stay safe and let it pass, most difficult experiences ease as the drug wears off.
- Get to a calm, safe space with someone you trust who is sober and can stay with you.
- Cool down if you’re overheating, move somewhere cool, remove extra layers, rest. Overheating is especially a risk with stimulants and MDMA.
- Sip water to thirst, but don’t over-hydrate. Drinking large amounts of plain water (especially after MDMA) can dangerously dilute your blood sodium (hyponatremia). Electrolytes help more than volume.
- Slow your breathing, long, slow exhales help settle a racing heart and anxiety.
- A sugary drink, fruit juice, or a snack can ease shakiness and the anxiety that comes with low blood sugar.
- Do not take more, and do not add another substance to manage it. Redosing or adding something else (including a sedative like a benzodiazepine) can make things worse, not better.
With stimulants, overheating and a racing heart are the main concerns, get somewhere cool, stop any physical activity, and don't take more.
Source: general harm-reduction guidance from SAMHSA, NIH/NIDA, and MedlinePlus, in our own words. Draft, not yet medically reviewed.
Forensic dossier
Draft · every field is source-cited or marked “Unknown, pending review”Identity
- PubChem CID
- 3007PubChem PUG-REST ↗ · retrieved 2026-06-18
- IUPAC name
- 1-phenylpropan-2-aminePubChem PUG-REST ↗ · retrieved 2026-06-18
- Molecular formula
- C9H13NPubChem PUG-REST ↗ · retrieved 2026-06-18
- SMILES
- CC(CC1=CC=CC=C1)NPubChem PUG-REST ↗ · retrieved 2026-06-18
- InChIKey
- KWTSXDURSIMDCE-UHFFFAOYSA-NPubChem PUG-REST ↗ · retrieved 2026-06-18
- Synonyms / aliases
- speed, Amfetamine, 1-phenylpropan-2-amine, dl-Amphetamine, 1-Phenyl-2-aminopropane, Desoxynorephedrine, Norephedrane, Elastonon, Fenopromin, Phenedrine, beta-AminopropylbenzenePubChem PUG-REST + seed aliases ↗ · retrieved 2026-06-18
Composition
- Composition
- N/A — single compound (see Identity)
Physical / pill characteristics
- Dosage form
- HUMAN PRESCRIPTION DRUGopenFDA drug label ↗ · retrieved 2026-06-18
- Shape
- Unknown — pending review (verify tablet imprint/shape against NLM Pillbox/DailyMed; N/A if not an oral tablet)
- Color
- Unknown — pending review (verify tablet imprint/shape against NLM Pillbox/DailyMed; N/A if not an oral tablet)
- Imprint
- Unknown — pending review (verify tablet imprint/shape against NLM Pillbox/DailyMed; N/A if not an oral tablet)
- Score
- Unknown — pending review (verify tablet imprint/shape against NLM Pillbox/DailyMed; N/A if not an oral tablet)
Scheduling & legal status
- US schedule
- Unknown — pending review
- International
- Unknown, pending review
Effects, risks & interactions
- Effects
- Amphetamine is a stimulant that increases the release of the neurotransmitters dopamine and noradrenaline. In medicine it treats ADHD and narcolepsy; its effects include heightened alertness, wakefulness, focus and energy, reduced appetite, and often a sense of confidence or, at higher exposure, euphoria. As a sympathomimetic it also raises heart rate and blood pressure. Where a therapeutic effect ends and a harmful one begins is largely a matter of dose and context.PubChem CID 3007 + DailyMed label ↗ · retrieved 2026-06-18
- Risks
- Amphetamine's foremost risks are cardiovascular: it pushes heart rate and blood pressure higher and, especially at high doses or in people with underlying heart disease, can contribute to arrhythmia, heart attack and stroke — sudden death has been reported in people with structural cardiac abnormalities. It can also drive dangerous overheating (hyperthermia). At high or chronic doses it can produce a stimulant psychosis — paranoia, hallucinations and agitation resembling a psychotic episode. Repeated use brings tolerance and dependence, followed by a depleted, low-mood "crash" and withdrawal on stopping.PubChem CID 3007 + DailyMed label ↗ · retrieved 2026-06-18
- Interactions
- Amphetamine's labelling warns most strongly against monoamine-oxidase inhibitors (MAOIs): pairing a CNS stimulant with an MAOI can trigger a hypertensive crisis whose potential outcomes include stroke, heart attack and death, so the two must never be combined — nor amphetamine used within two weeks of stopping an MAOI. The label also notes that agents which alkalinize the gut or urine push amphetamine blood levels up while acidifying agents pull them down, and that amphetamine can blunt the effect of some blood-pressure medicines.DailyMed §7 Drug Interactions ↗ · retrieved 2026-06-18
Pill catalog
Rx/OTC variants · openFDA + DailyMed (public domain) · draft, pending reviewThis drug comes in 300different versions. Make sure you’re looking at the right one, use the search above to find your exact pill by imprint, color, or shape.
Showing 24 of 300 variants
- Strength
- AMPHETAMINE ASPARTATE MONOHYDRATE 2.5 mg/1; AMPHETAMINE SULFATE 2.5 mg/1; DEXTRO
- Imprint
- M Amphet Salts 10 mg
- Color
- BLUE
- Shape
- CAPSULE
- Form
- CAPSULE, EXTENDED RELEASE
- Labeler
- Sandoz Inc
- Schedule
- CII
- NDC
- 0781-2335 ↗ · 2026-06-18
- Strength
- AMPHETAMINE ASPARTATE MONOHYDRATE 2.5 mg/1; AMPHETAMINE SULFATE 2.5 mg/1; DEXTRO
- Imprint
- N31
- Color
- BLUE
- Shape
- ROUND
- Form
- TABLET
- Labeler
- SUNRISE PHARMACEUTICAL, INC.
- Schedule
- CII
- NDC
- 11534-192 ↗ · 2026-06-18
- Strength
- AMPHETAMINE ASPARTATE MONOHYDRATE 2.5 mg/1; AMPHETAMINE SULFATE 2.5 mg/1; DEXTRO
- Imprint
- Unknown — pending review
- Color
- Unknown — pending review
- Shape
- Unknown — pending review
- Form
- TABLET
- Labeler
- Bryant Ranch Prepack
- Schedule
- CII
- NDC
- 71335-1249 ↗ · 2026-06-18
- Strength
- AMPHETAMINE ASPARTATE MONOHYDRATE 1.25 mg/1; AMPHETAMINE SULFATE 1.25 mg/1; DEXT
- Imprint
- N29
- Color
- BLUE
- Shape
- ROUND
- Form
- TABLET
- Labeler
- SUNRISE PHARMACEUTICAL, INC.
- Schedule
- CII
- NDC
- 11534-190 ↗ · 2026-06-18
- Strength
- AMPHETAMINE ASPARTATE MONOHYDRATE 1.875 mg/1; AMPHETAMINE SULFATE 1.875 mg/1; DE
- Imprint
- N30
- Color
- BLUE
- Shape
- ROUND
- Form
- TABLET
- Labeler
- SUNRISE PHARMACEUTICAL, INC.
- Schedule
- CII
- NDC
- 11534-191 ↗ · 2026-06-18
- Strength
- AMPHETAMINE ASPARTATE MONOHYDRATE 2.5 mg/1; AMPHETAMINE SULFATE 2.5 mg/1; DEXTRO
- Imprint
- E 111
- Color
- BLUE
- Shape
- ROUND
- Form
- TABLET
- Labeler
- Sandoz Inc
- Schedule
- CII
- NDC
- 0185-0842 ↗ · 2026-06-18
- Strength
- AMPHETAMINE ASPARTATE 2.5 mg/1; AMPHETAMINE SULFATE 2.5 mg/1; DEXTROAMPHETAMINE
- Imprint
- Unknown — pending review
- Color
- Unknown — pending review
- Shape
- Unknown — pending review
- Form
- TABLET
- Labeler
- Bryant Ranch Prepack
- Schedule
- CII
- NDC
- 71335-0171 ↗ · 2026-06-18
- Strength
- AMPHETAMINE DL-ASPARTATE MONOHYDRATE 1.25 mg/1; AMPHETAMINE SULFATE 1.25 mg/1; D
- Imprint
- AMG 277
- Color
- GREEN
- Shape
- CAPSULE
- Form
- CAPSULE, EXTENDED RELEASE
- Labeler
- ANI Pharmaceuticals, Inc.
- Schedule
- CII
- NDC
- 43975-277 ↗ · 2026-06-18
- Strength
- AMPHETAMINE ASPARTATE MONOHYDRATE 7.5 mg/1; AMPHETAMINE SULFATE 7.5 mg/1; DEXTRO
- Imprint
- 30 mgM 8956
- Color
- orange
- Shape
- CAPSULE
- Form
- CAPSULE, EXTENDED RELEASE
- Labeler
- SpecGx LLC
- Schedule
- CII
- NDC
- 0406-8956 ↗ · 2026-06-18
- Strength
- AMPHETAMINE ASPARTATE MONOHYDRATE 3.125 mg/1; AMPHETAMINE SULFATE 3.125 mg/1; DE
- Imprint
- N32
- Color
- ORANGE
- Shape
- ROUND
- Form
- TABLET
- Labeler
- SUNRISE PHARMACEUTICAL, INC.
- Schedule
- CII
- NDC
- 11534-193 ↗ · 2026-06-18
- Strength
- AMPHETAMINE ASPARTATE MONOHYDRATE 6.25 mg/1; AMPHETAMINE SULFATE 6.25 mg/1; DEXT
- Imprint
- Unknown — pending review
- Color
- Unknown — pending review
- Shape
- Unknown — pending review
- Form
- CAPSULE, EXTENDED RELEASE
- Labeler
- Lannett Company, Inc.
- Schedule
- CII
- NDC
- 0527-0794 ↗ · 2026-06-18
- Strength
- AMPHETAMINE ASPARTATE MONOHYDRATE 3.75 mg/1; AMPHETAMINE SULFATE 3.75 mg/1; DEXT
- Imprint
- N33
- Color
- ORANGE
- Shape
- ROUND
- Form
- TABLET
- Labeler
- SUNRISE PHARMACEUTICAL, INC.
- Schedule
- CII
- NDC
- 11534-194 ↗ · 2026-06-18
- Strength
- AMPHETAMINE ASPARTATE MONOHYDRATE 5 mg/1; AMPHETAMINE SULFATE 5 mg/1; DEXTROAMPH
- Imprint
- N34
- Color
- ORANGE
- Shape
- ROUND
- Form
- TABLET
- Labeler
- SUNRISE PHARMACEUTICAL, INC.
- Schedule
- CII
- NDC
- 11534-195 ↗ · 2026-06-18
- Strength
- AMPHETAMINE DL-ASPARTATE MONOHYDRATE 6.25 mg/1; AMPHETAMINE SULFATE 6.25 mg/1; D
- Imprint
- AMG 281
- Color
- PINK
- Shape
- CAPSULE
- Form
- CAPSULE, EXTENDED RELEASE
- Labeler
- ANI Pharmaceuticals, Inc.
- Schedule
- CII
- NDC
- 43975-281 ↗ · 2026-06-18
- Strength
- AMPHETAMINE ASPARTATE MONOHYDRATE 5 mg/1; AMPHETAMINE SULFATE 5 mg/1; DEXTROAMPH
- Imprint
- Lannett 0793
- Color
- orange
- Shape
- CAPSULE
- Form
- CAPSULE, EXTENDED RELEASE
- Labeler
- Golden State Medical Supply, Inc.
- Schedule
- CII
- NDC
- 51407-560 ↗ · 2026-06-18
- Strength
- AMPHETAMINE ASPARTATE MONOHYDRATE 2.5 mg/1; AMPHETAMINE SULFATE 2.5 mg/1; DEXTRO
- Imprint
- G10 113
- Color
- white
- Shape
- OVAL
- Form
- TABLET
- Labeler
- Granules Pharmaceuticals Inc.
- Schedule
- CII
- NDC
- 70010-113 ↗ · 2026-06-18
- Strength
- AMPHETAMINE ASPARTATE MONOHYDRATE 7.5 mg/1; AMPHETAMINE SULFATE 7.5 mg/1; DEXTRO
- Imprint
- N35
- Color
- ORANGE
- Shape
- ROUND
- Form
- TABLET
- Labeler
- SUNRISE PHARMACEUTICAL, INC.
- Schedule
- CII
- NDC
- 11534-196 ↗ · 2026-06-18
- Strength
- AMPHETAMINE DL-ASPARTATE MONOHYDRATE 2.5 mg/1; AMPHETAMINE SULFATE 2.5 mg/1; DEX
- Imprint
- AMG 278
- Color
- GREEN
- Shape
- CAPSULE
- Form
- CAPSULE, EXTENDED RELEASE
- Labeler
- ANI Pharmaceuticals, Inc.
- Schedule
- CII
- NDC
- 43975-278 ↗ · 2026-06-18
- Strength
- AMPHETAMINE ASPARTATE MONOHYDRATE 1.25 mg/1; AMPHETAMINE SULFATE 1.25 mg/1; DEXT
- Imprint
- LANNETT 0790
- Color
- white
- Shape
- CAPSULE
- Form
- CAPSULE, EXTENDED RELEASE
- Labeler
- Golden State Medical Supply, Inc.
- Schedule
- CII
- NDC
- 51407-557 ↗ · 2026-06-18
- Strength
- AMPHETAMINE ASPARTATE MONOHYDRATE 1.25 mg/1; AMPHETAMINE SULFATE 1.25 mg/1; DEXT
- Imprint
- G5 111
- Color
- white
- Shape
- OVAL
- Form
- TABLET
- Labeler
- Granules Pharmaceuticals Inc.
- Schedule
- CII
- NDC
- 70010-111 ↗ · 2026-06-18
- Strength
- AMPHETAMINE DL-ASPARTATE MONOHYDRATE 3.75 mg/1; AMPHETAMINE SULFATE 3.75 mg/1; D
- Imprint
- AMG 279
- Color
- GREEN
- Shape
- CAPSULE
- Form
- CAPSULE, EXTENDED RELEASE
- Labeler
- ANI Pharmaceuticals, Inc.
- Schedule
- CII
- NDC
- 43975-279 ↗ · 2026-06-18
- Strength
- AMPHETAMINE ASPARTATE MONOHYDRATE 2.5 mg/1; AMPHETAMINE SULFATE 2.5 mg/1; DEXTRO
- Imprint
- Lannett 0791
- Color
- blue
- Shape
- CAPSULE
- Form
- CAPSULE, EXTENDED RELEASE
- Labeler
- Golden State Medical Supply, Inc.
- Schedule
- CII
- NDC
- 51407-558 ↗ · 2026-06-18
- Strength
- AMPHETAMINE ASPARTATE MONOHYDRATE 1.875 mg/1; AMPHETAMINE SULFATE 1.875 mg/1; DE
- Imprint
- G7 5 112
- Color
- white
- Shape
- ROUND
- Form
- TABLET
- Labeler
- Granules Pharmaceuticals Inc.
- Schedule
- CII
- NDC
- 70010-112 ↗ · 2026-06-18
- Strength
- AMPHETAMINE DL-ASPARTATE MONOHYDRATE 5 mg/1; AMPHETAMINE SULFATE 5 mg/1; DEXTROA
- Imprint
- AMG 280
- Color
- PINK
- Shape
- CAPSULE
- Form
- CAPSULE, EXTENDED RELEASE
- Labeler
- ANI Pharmaceuticals, Inc.
- Schedule
- CII
- NDC
- 43975-280 ↗ · 2026-06-18
Dosage
Pending medical reviewer
